Findings

What do systematic reviews say?

504 questions · 511 findings · 66 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 104 · 20.4%GRADE not reported 26 · 5.1%Very low 107 · 20.9%Low 129 · 25.2%Moderate 107 · 20.9%High 38 · 7.4%

Summary of findings: 5 mg/day vs placebo

Function ‐ not measured · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs placebo

Harms · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs placebo

Headache ‐ not reported4 · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Benefits · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Pain ‐ not reported1 · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Symptom free with activities of daily living (patient rated) ( · rotator cuff disease

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in symptom free with activities of daily living (patient rated) ( compared with placebo plus rehabilitation (low certainty).

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
RR 1.92 [0.92, 4.1]
1 study · 57 participants
Low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Clinical improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.19 [0.37, 3.77]
1 study · 39 participants
Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.63 [0.12, 3.38]
1 study · 39 participants
Very low

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Clinical improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 2.5 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.56 [0.23, 1.37]
1 study · 40 participants
Very low

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Histological improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2 [0.2, 20.33]
1 study · 40 participants
Very low